ArticleCurrent journal of neurology2021

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis.

Nayyereh Ayati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.